@article{oai:kanazawa-u.repo.nii.ac.jp:00055263,
 author = {佐々木, 宗一郎 and 向田, 直史 and 馬場, 智久 and Tanabe, Yamato and Sasaki, Soichiro and Mukaida, Naofumi and Baba, Tomohisa},
 issue = {30},
 journal = {Oncotarget},
 month = {Jul},
 note = {We previously demonstrated that cancer-associated fibroblasts (CAFs) accumulate at tumor sites through the interaction between a chemokine, CCL3, and its receptor, CCR5, in the late phase of colitis-associated colon carcinogenesis. Here we examined the effect of a CCR5 antagonist, maraviroc, on tumor growth arising from the orthotopic injection of mouse or human colon cancer cell lines into the cecal wall by focusing on CAFs. Orthotopic injection of either cell line caused tumor formation together with leukocyte infiltration and fibroblast accumulation. Concomitant oral administration of maraviroc reduced tumor formation with few effects on leukocyte infiltration. In contrast, maraviroc reduced the intratumor number of α-smooth muscle actin-positive fibroblasts, which express epidermal growth factor, a crucial growth factor for colon cancer cell growth. These observations suggest that maraviroc or other CCR5 antagonists might act as novel anti-CRC drugs to dampen CAFs, an essential cell component for tumor progression., This work was supported by a Grant-in-Aid for Young Scientists (B) 15K18406 from the Japan Society for the Promotion of Science (JSPS)., 金沢大学がん進展制御研究所},
 pages = {48335--48345},
 title = {Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation},
 volume = {7},
 year = {2016}
}